Juan José
Lasarte Sagastibelza
Catedrático de Universidad
Clínica Universitaria de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (10)
2024
-
Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model
Journal for immunotherapy of cancer, Vol. 12, Núm. 7
2022
-
Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 8
2021
-
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3
2020
-
The involvement of ADAM10 in acantholysis in mucocutaneous pemphigus vulgaris depends on the autoantibody profile of each patient
British Journal of Dermatology, Vol. 182, Núm. 5, pp. 1194-1204
2017
-
Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)
PLoS ONE, Vol. 12, Núm. 9
2011
-
Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10
Hepatology, Vol. 53, Núm. 1, pp. 23-31
2005
-
Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex
Vaccine, Vol. 23, Núm. 11, pp. 1384-1392
2002
-
Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen
Clinical Cancer Research, Vol. 8, Núm. 10, pp. 3219-3225
1998
-
Defective recombinant adenoviruses as a tool to induce anti-HCV immune responses
Biotecnologia Aplicada, Vol. 15, Núm. 3, pp. 195
1997
-
Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C
Gastroenterology, Vol. 113, Núm. 5, pp. 1647-1653